• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Kiromic Biopharma Inc (NQ: KRBP )

    N/A UNCHANGED
    Last Price Updated: 4:00 PM EDT, Sep 13, 2023 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Kiromic Biopharma Inc

    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Kiromic BioPharma Reports Favorable Results at Six Weeks from Fourth Patient in Deltacel-01 Clinical Trial
    From Kiromic BioPharma, Inc.
    Via Business Wire
    Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site
    From Kiromic BioPharma, Inc.
    Via Business Wire
    KRBP Stock Earnings: Kiromic BioPharma Reported Results for Q1 2024
    Kiromic BioPharma just reported results for the first quarter of 2024. 
    Via InvestorPlace
    Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients
    From Kiromic BioPharma, Inc.
    Via Business Wire
    Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial
    From Kiromic BioPharma, Inc.
    Via Business Wire
    Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial
    From Kiromic BioPharma, Inc.
    Via Business Wire
    Life Science Virtual Investor Forum Presentations Now Available for Online Viewing
    Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
    From Virtual Investor Conferences
    Via GlobeNewswire
    Life Science Virtual Investor Forum Agenda Announced for March 7th, 2024
    Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
    From Virtual Investor Conferences
    Via GlobeNewswire
    Kiromic BioPharma Adds Virginia Oncology Associates, PC as the Second Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial
    From Kiromic BioPharma, Inc.
    Via Business Wire
    Kiromic BioPharma to Present at the OTC Markets’ Virtual Life Science Investor Forum on March 7th
    From Kiromic BioPharma, Inc.
    Via Business Wire
    Kiromic BioPharma to Present at the OTC Markets’ Virtual Life Science Investor Forum on March 7th
    Live and Archived Fireside Chat Available at VirtualInvestorConferences.com 
    From Virtual Investor Conferences
    Via GlobeNewswire
    Results from First Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months
    From Kiromic BioPharma, Inc.
    Via Business Wire
    Kiromic BioPharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung Cancer
    From Kiromic BioPharma, Inc.
    Via Business Wire
    Kiromic BioPharma Reports Favorable Early Safety and Tolerability Data from First Patient Enrolled in the Phase 1 Deltacel-01 Clinical Trial
    From Kiromic BioPharma, Inc.
    Via Business Wire
    Kiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel™ for the Treatment of Non-Small Cell Lung Cancer
    From Kiromic BioPharma, Inc.
    Via Business Wire
    Kiromic BioPharma Announces Uplisting to OTCQB Market
    From Kiromic BioPharma, Inc.
    Via Business Wire
    Kiromic BioPharma Announces Deltacel™ Phase 1 Clinical Trial Enters Patient Recruitment Phase at Beverly Hills Cancer Center
    From Kiromic BioPharma, Inc.
    Via Business Wire
    Kiromic BioPharma and Beverly Hills Cancer Center Enter Clinical Trial Agreement
    From Kiromic BioPharma, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    Kiromic BioPharma Common Stock to Begin Trading on the OTC Pink Sheets on September 14
    From Kiromic BioPharma
    Via Business Wire
    Stocks That Hit 52-Week Lows On Tuesday
      On Tuesday, 46 stocks hit new 52-week lows. 
    Via Benzinga
    Kiromic BioPharma Welcomes Two New Directors to its Board
    From Kiromic BioPharma, Inc.
    Via Business Wire
    Stocks That Hit 52-Week Lows On Friday
      Friday's session saw 59 companies set new 52-week lows. 
    Via Benzinga
    Why Cineverse Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Gainers Addentax Group Corp. (NASDAQ: ATXG) shares jumped 47.3% to $9.68. Addentax Group is launching automation of artificial intelligence internet operational tools project with top... 
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    Why Renalytix Are Trading Higher By Over 48%; Here Are 20 Stocks Moving Premarket
    Gainers Renalytix Plc (NASDAQ: RNLX) shares surged 48.7% to $3.02 in pre-market trading after the company received FDA De Novo marketing authorization for its KidneyIntelX.dkd prognostic test. 
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
    It's the final day of trading this week and we're starting off with a breakdown of the biggest pre-market stock movers worth watching today! 
    Via InvestorPlace
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    What's Going On With Kiromic BioPharma Stock Wednesday
    Kiromic BioPharma Inc (NASDAQ: KRBP) shares are gaining Wednesday morning. However, there is no specific news today. During the session, the share price reached $9.22. 
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.